FDA Approved: FLUDEOXYGLUCOSE F18 — Supplemental Application (THE FEINSTEIN INSTITUTE FOR MEDICAL RESEARCH)

View source ↗

Summary

FDA approved a supplemental application for Fludeoxyglucose F18, a PET imaging radiopharmaceutical, expanding its regulatory status.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Alzheimer Disease
• Cancer
• Epilepsy

Drugs mentioned

• Fludeoxyglucose F18 (Fludeoxyglucose F18)

Snippet

SUPPL AP for FLUDEOXYGLUCOSE F18 (FLUDEOXYGLUCOSE F18)